Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by pericles1on Sep 01, 2011 12:34am
257 Views
Post# 19001186

RE: Pericles - Input Please

RE: Pericles - Input Please

Jeez, Singing or Gemini have you not listened to the conference calls. Phase III B is set in concrete it's really not how effective is Reolysin it's all about safety. No matter how successfull Phase III A is the FDA will not approve without many more in the sample for safety reasons and you cannot find that out by giving everyone  Reolysin! 

 Does it slow enrollment to have a placebo arm, you bet, but after the information on Phase III A is reported and if it shows the kind of result I expect it may help with people even wanting a chance at 50%.

As for timing enrollment in Phase A will be done in the fourth quarter per Brad but the information needs to mature some before being reported so my estimate of mid year. That means that B stage enrollment will start before the end of the year.
Bullboard Posts